P2Y12 blocker monotherapy after percutaneous coronary intervention
Autor: | P. Damman, F W A Verheugt, J J Wykrzykowska, R J van Geuns, Sander Damen, E C I Woelders |
---|---|
Rok vydání: | 2021 |
Předmět: |
medicine.medical_specialty
Ticagrelor Prasugrel animal structures medicine.medical_treatment Vascular damage Radboud Institute for Health Sciences [Radboudumc 16] Review Article VALIDATION Percutaneous coronary intervention Coronary artery disease P2Y12 TICLOPIDINE Internal medicine medicine cardiovascular diseases STENT IMPLANTATION CARDIOVASCULAR EVENTS Aspirin business.industry PCI medicine.disease Clopidogrel Conventional PCI Cardiology Cardiology and Cardiovascular Medicine business medicine.drug DUAL-ANTIPLATELET THERAPY |
Zdroj: | Netherlands Heart Journal Netherlands Heart Journal, 29, 11, pp. 566-576 Netherlands Heart Journal, 29, 566-576 |
ISSN: | 1568-5888 |
Popis: | Contains fulltext : 245705.pdf (Publisher’s version ) (Open Access) For secondary prevention of coronary artery disease (CAD) antiplatelet therapy is essential. For patients undergoing a percutaneous coronary intervention (PCI) temporary dual antiplatelet platelet therapy (DAPT: aspirin combined with a P2Y12 blocker) is mandatory, but leads to more bleeding than single antiplatelet therapy with aspirin. Therefore, to reduce bleeding after a PCI the duration of DAPT is usually kept as short as clinically acceptable; thereafter aspirin monotherapy is administered. Another option to reduce bleeding is to discontinue aspirin at the time of DAPT cessation and thereafter to administer P2Y12 blocker monotherapy. To date, five randomised trials have been published comparing DAPT with P2Y12 blocker monotherapy in 32,181 stented patients. Also two meta-analyses addressing this novel therapy have been presented. P2Y12 blocker monotherapy showed a 50-60% reduction in major bleeding when compared to DAPT without a significant increase in ischaemic outcomes, including stent thrombosis. This survey reviews the findings in the current literature concerning P2Y12 blocker monotherapy after PCI. |
Databáze: | OpenAIRE |
Externí odkaz: |